"The last time you scooped some ice cream for dessert, did you limit yourself to half a cup? If you took more - say, one cup - you're right in step with most people these days.
Likewise with a soft drink: Do you drink 8 ounces or t"...
(Generic versions may still be available.)
Redux Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Redux (dexfenfluramine hydrochloride) is a serotonin reuptake inhibitor and releasing agent used to manage obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include diarrhea, dry mouth, and drowsiness.
The usual dosage of Redux is one 15-mg capsule twice daily, with meals. Redux may interact with monoamine oxidase inhibitors (MAOIs), medications to treat migraines, other serotoninergic agents, and other CNS-active drugs. Tell your doctor all medications and supplements you use. Redux is not recommended for use during pregnancy. It is unknown if this drug passes into breast milk. Breastfeeding while using this drug is not recommended.
Our Redux (dexfenfluramine hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Redux FDA Prescribing Information: Side Effects
The most commonly observed, treatment-emergent adverse events associated with the use of dexfenfluramine in double-blind, placebo-controlled clinical trials were diarrhea (17.5%), dry mouth (12.5%), and somnolence (7.1%). These and other commonly observed adverse reactions were generally mild and transient. (Commonly observed is defined as incidence of 5% or greater and incidence in dexfenfluramine group at least twice that of placebo group, as derived from the Table 3 below.)
Associated with Discontinuation of Treatment
Seven percent of the 1159 patients who received dexfenfluramine in double-blind, placebo-controlled clinical trials discontinued treatment because of an adverse event. The most common adverse events resulting in discontinuation included asthenia, insomnia, headache, and depression. Five percent of the 1138 placebo-treated patients discontinued because of an adverse event.
Incidence in Controlled Clinical Trials
The following Table 3 lists treatment-emergent adverse events from several double-blind, placebo-controlled trials that occurred at a frequency of 2% or more among patients treated with dexfenfluramine and occurred at least as frequently as the placebo group, regardless of relationship to study medication.
Other Events Observed in Controlled Clinical Trials
The events below are classified within body system categories and enumerated in order of decreasing frequency using the following definitions. Frequent adverse events are those occurring in more than 1/100 patients but were not described above because the frequency in dexfenfluramine-treated patients was less than that in placebo-treated patients or they occurred at a rate less than 2%. Infrequent adverse events are those occurring in 1/100 to 1/1000 patients, while rare adverse events are those occurring in only one patient during placebo-controlled clinical trials.
Body as a whole:
Hemic and lymphatic system:
Metabolic and nutritional:
Infrequent: tremor, amnesia, euphoria, decreased libido, incoordination, neuralgia, speech disorder, ataxia, hypokinesia, sleep disorder, abnormal gait, agitation, confusion, depersonalization, diplopia, hostility, hyperesthesia, hyperkinesia, peripheral neuritis.
Skin and appendages:
Rare: skin hypertrophy.
Rare: spontaneous abortion, threatened abortion, breast neoplasm, endometrial disorder, female lactation, hematuria, impotence, mastitis, nephritis, prostatic disorder, testis disorder, urinary incontinence, urinary retention, uterine hemorrhage.
In controlled clinical trials, there has been no consistent pattern of laboratory abnormalities in patients treated with dexfenfluramine.
Voluntary reports of adverse events temporally associated with dexfenfluramine that have been received since market introduction in countries other than the US, for which the association with the drug is unknown, and which are not included in descriptions of adverse events elsewhere in this labeling, include the following:
Cardiovascular system: pulmonary hypertension (see WARNINGS), atrial fibrillation, cardiomyopathy, cerebral vasculitis, ECG abnormal, heart arrest, heart failure, myocardial infarction, myocarditis, shock, tachycardia, ventricular fibrillation, ventricular tachycardia.
Digestive system: dysphagia, gastrointestinal disorder, tongue disorder. Endocrine system--diabetic coma.
Nervous system: antisocial reaction, apathy, cerebellar ataxia, cerebrovascular accident (including cerebral hemorrhage, cerebral infarction, cerebral ischemia and cochlear infarction), choreoathetosis, convulsions, decreased reflexes, delirium, drug dependence, dyslexia, encephalopathy, grand mal convulsions, Guillain-Barré syndrome, hemiplegia, hypoesthesia, manic-depressive psychosis, manic reaction, memory loss, meningism, meningitis, neuropathy, papilledema, paraplegia, personality disorder, reflexes increased, retrobulbar neuritis, schizophrenic reaction, stupor, subdural hematoma, twitch, withdrawal syndrome.
Adverse Events Occurring After Discontinuation
In controlled clinical trials and/or in post-marketing reports, symptoms have been reported within a few days after discontinuation of dexfenfluramine. These include one or more of the following: abdominal pain, anxiety, asthenia, delusion, depression, diarrhea, dizziness, hypertension, insomnia, nausea and vomiting.
DRUG ABUSE AND DEPENDENCE
Controlled Substance Class
Dexfenfluramine is a controlled substance in Schedule IV.
Abuse and Physical and Psychological Dependence
Dexfenfluramine is not an amphetamine or a stimulant. There is no evidence of addictive or drug-seeking behavior in pre-marketing clinical studies. Dexfenfluramine was inactive in rat and monkey self-administration, drug-discrimination, and place-preference models of abuse potential.
Read the entire FDA prescribing information for Redux (Dexfenfluramine (FDA Removed From US Market 9/15/97))
Additional Redux Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.